Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials
Source : https://www.medsci.org/v19p1118.htm
Int J Med Sci 2022; 19(7):1118-1121. doi:10.7150/ijms.72772 This issue Review Bo Liang 1,2, Ning Gu 3 1. Nanjing University of Chinese Medicine, Nanjing, China.2. Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.3. Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Relevance: Here, we summarize the latest and current understanding of the management for patients with established heart failure and type 2 diabetes mellitus and further present contemporary treatment options, sodium-glucose co-transporter-2 inhibitor, for these particular populations.